The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the Plavix Response in Coronary Intervention (PRINC) trial ACTRN12606000129583.

Slides:



Advertisements
Similar presentations
Introduction: In the setting of a suspected acute coronary syndrome (ACS), aspirin (ASA) is the primary treatment used for platelet inhibition. However,
Advertisements

ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning” A Report of the American College of Cardiology Foundation Task Force on Clinical.
CZ5225 Methods in Computational Biology Lecture 9: Pharmacogenetics and individual variation of drug response CZ5225 Methods in Computational Biology.
Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients treated with Percutaneous Coronary Intervention. Relationship with Gene.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes The PLATO PLATELET Substudy Storey.
1 SUPERIORITY OF A HIGH CLOPIDOGREL LOADING DOSE REGIMEN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: EVIDENCE FROM A META-ANALYSIS G. BIONDI-ZOCCAI1,
Assessment of the best Loading dose of clopidogrel to Blunt platelet activation, Inflammation and Ongoing Necrosis ALBION.
Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease Aspirin and clopidogrel: - Reduce the risks of myocardial infarction, ischemic.
Hepatic generation of active metabolite Pharmacogenetics of Cardiovascular Antithrombotic Therapy CYP = cytochrome P450. GP = glycoprotein. MDR = multidrug.
Pharmacology in Acute Coronary Syndromes: Anti-platelet Agents Tim Kinnaird, University Hospital Wales, Cardiff and Vale NHS Trust.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel TRITON-TIMI 38 TRITON-TIMI 38 Elliott M. Antman, MD.
Brar et al, JACC 2011 Impact of Platelet Reactivity When On-treatment With Clopidogrel on Mortality, MI or Stent Thrombosis After PCI Impact of Platelet.
Measurement of Clopidogrel Resistance by ADP-Inhibition Does Not Reflect the Benefit of Clopidogrel on Overall Thrombotic Status Dr Diana A Gorog Consultant.
Point of Care Platelet Function Testing – Is There Still Value?
Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.
Introduction Clopidogrel is metabolized by P450 (CYP)-isoenzymes: CYP 3A4/5, 1A2, 2B6, 2C9, and 2C19 1 Wide response variability and nonresponsiveness.
High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Clinical Trial Results. org Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients with Diabetes Mellitus and Coronary Artery Disease:
* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):
The Additive Value of Tirofiban Administered With the High-Dose Bolus in the Prevention of Ischemic Complications During High-Risk Coronary Angioplasty.
Clinical Trial Results. org Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary.
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
1 HIGH CLOPIDOGREL LOADING DOSE IS SUPERIOR TO A STANDARD 300 MG REGIMEN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: EVIDENCE FROM A META-ANALYSIS.
Copyleft Clinical Trial Results. You Must Redistribute Slides The American College of Cardiology Foundation / American Heart Association Clopidogrel Recommendations.
¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.
Trial Vignettes Cameron G Densem TRITON-TIMI 38 ARMYDA OPTIMA.
- Published online December 23, 2008 DOI: /S (08) Study sponsored and funded by Assistance Publique.
Hepatitis web study Hepatitis web study Daclatasvir + Asunaprevir + Peg/RBV in Genotype 1 and 4 HALLMARK-QUAD Study Phase 3 Treatment-Experienced Jensen.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2:ARMYDA-2:
Measurement of Antiplatelet Therapeutic Efficacy Bonnie H. Weiner MD MSEC MBA FSCAI FACC FAHA Professor of Medicine Director, Interventional Cardiology.
Adapted from Angiolillo DJ et al. Am J Cardiol. 2006;97: Individual Response Variability to Dual Antiplatelet Therapy in the Steady State Phase of.
Rossella Marcucci, MD; Anna Maria Gori, BS; Rita Paniccia, BS; Betti Giusti, BS; Serafina Valente, MD; Cristina Giglioli, MD; Piergiovanni Buonamici, MD;
Mega JL, et al. N Engl J Med 2009;360: Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel.
How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.
The Big Antiplatelet Debate: Why I Prefer Ticagrelor Over Prasugrel
PhenGene P2Y12 Test.
Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI
Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.
Anne Masich, PharmD PGY1 Resident University of Maryland
Randomisation before planned PCI with DES (n=2500)
Matthew J. Price MD Director, Cardiac Catheterization Laboratory,
Genotyping: Which One Should we Perform? How to Interpret the Data?
The GRAVITAS trial Matthew J. Price MD, FACC, FSCAI
Smoking Paradox for Clopidogrel : : Is It a Myth or Truth?
Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Megha Kureti, MD, Deepa Nagaraju, MD, Mustafa Wali,
Learning Objectives. Learning Objectives Variable Response to Clopidogrel.
11/12/2018 CYP2C19-Clopidogrel Development of these slides was supported by funding from the IGNITE Network. When using or adapting any of these slides.
11/12/2018 CYP2C19-Clopidogrel Development of these slides was supported by funding from the IGNITE Network. When using or adapting any of these slides.
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Nat. Rev. Cardiol. doi: /nrcardio
Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Emerging Data Regarding the Potential Benefits of Early Initiation of Clopidogrel Among ACS Patients C. Michael Gibson, M.S., M.D.
International Journal of Cardiology
Update on the New Antiplatelet Agents:
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.
Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.
Fourteen (28%) of 50 patients met the criteria of nonresponse with test results of over 52 AU. Patient 1 received a second full loading dose of 300 mg.
Presentation transcript:

The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the Plavix Response in Coronary Intervention (PRINC) trial ACTRN Gladding PA, 1 Webster MW, 1 Zeng I, 1 Farrell H, 1 Stewart J, 1 Ruygrok P, 1 Ormiston J, 2 Gunes A, 3 Perry J, Dahl M-L. 1 Green Lane Cardiovascular Department 3 Liggins Institute, Auckland, NZ 2 Uppsala University, Sweden Funded by GLREF, NHF Support from Sanofi NZ

Optimal Clopidogrel Dosing Important for two reasons:Important for two reasons: 1.Antiplatelet effect at PCI corresponds with periprocedural infarction (ARMYDA-2) 2.Timing: Dosing <6-10hrs prior to PCI ineffective (CREDO) Three recent studies have indicated that doses >600mg are not more effective than 600mgThree recent studies have indicated that doses >600mg are not more effective than 600mg

Aims To compare a higher split loading dose of clopidogrel (600mg + 600mg) with standard 600mgTo compare a higher split loading dose of clopidogrel (600mg + 600mg) with standard 600mg Compare 150mg with 75mg once dailyCompare 150mg with 75mg once daily Investigate the pharmacogenomics of clopidogrelInvestigate the pharmacogenomics of clopidogrel

Methods N=36 150mg/day Clopidogrel

VerifyNow Platelet Function Analyser

VerifyNow P2Y12 assay correlates well with Gold standard LTA van Werkum JW et al. J Thromb Haemost 2006;4(11):

Results of the PRINC (Plavix Response in Coronary Intervention) trial.

Randomisation Effective Patients Well Matched in All Treatment Groups c.f age

PRINCe study Non-responders

Increase in Periprocedural MI (7hrs) in Clopidogrel Nonresponders data presented are median (interquartile) 7 hours %inhibition > 10% 7 hours %inhibition ≤ 10% p value* N=52N=8 Troponin at 7 hours 0.01(0.01,0.03)0.05(0.01,0.29)0.05 *Mann Whitney U test

Drug Response is Predictable Within the First Few Hours r = 0.72 p < r = 0.65 p < r = 0.62 p < r = 0.75 p < r = 0.80 p < r = 0.72 p < <2% platelet inhibition at 2 hrs predicts nonresponder status at 7hrs (sensitivity 100%, specificity 88%) <2% platelet inhibition at 2 hrs predicts non- responder status at 7hrs (sensitivity 100%, specificity 88%)

1,200mg Split Dose of Clopidogrel is More Effective than Single LD P = 0.03 Standard 600mg dose Additional 600mg dose 1,200mg split dose n = mg dose n = 23

150mg Clopidogrel OD has a Greater Antiplatelet Effect than 75mg OD 49.8% 5.5% 3.7% 28.8% P = 0.01

Safety Adverse Event: 600mg1,200mg GIVomitingDiarrhoea0011 Rash00 BleedingMinorMajor1001

Biotransformation by CYP3A4, 3A5, C219, 2C9, 1A2 Polymorphic variants Clopidogrel Pharmacogenomics MDR1 C3435T genotype P2Y12 Receptor: H2 haplotype

CYP2C19 Genetic Variants Influence Clopidogrel Response

No benefit of higher dosing in normal *1 genotypes

Loss of function carriers respond to higher doses

Finding validated in higher maintenance dosing group

Conclusion Split loading with 600mg + 600mg (2hrs) clopidogrel increases the antiplatelet effectSplit loading with 600mg + 600mg (2hrs) clopidogrel increases the antiplatelet effect 150mg OD > 75mg OD antiplatelet effect150mg OD > 75mg OD antiplatelet effect Response can be measured robustly with a POC analyser & predicted early (2hrs)Response can be measured robustly with a POC analyser & predicted early (2hrs) Pharmacogenetics might predict response before Rx but phenotyping is still very effectivePharmacogenetics might predict response before Rx but phenotyping is still very effective

Jo Perry Mark Webster Ralph Stewart Irene Zeng Helen Farrell Arzu Gunes M-L Dahl Auckland City Hospital Pharmacy Clinical Trials Unit